BIO released a video explaining drug costs; the FDA commits to shorter generic approval process; Kaléo to launch EpiPen competitor
The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.
GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus
Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market
Aetna inks value-based deal with Merck in diabetes; new research claims co-pay cards increased drug spend; Xarelto data not affected by device
Opdivo fails in lung cancer trial; hedge fund sues Theranos; Takeda and Crescendo partner to develop humabody-based therapies
The FDA to require black-box warnings for hep.-C drugs; AstraZeneca's Brilinta fails to meet study goals; ICER says PD-1s are too pricey
Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.
The agency's ambitions were fueled in part by external criticism. The barbs that stung most sharply were ones suggesting a certain indifference on the FDA's part.
Five decades ago, pharmaceuticals were the protected province of health professionals. Today we have DTC ads, the internet, and pharmacy handouts.
The organizations are using innovation competitions to challenge internal and external audiences with coming up with new ideas.
Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.
The FDA approves a combination of aspirin and heartburn medication; Teva partners with Intel to develop wearable; New Mexico AG sues BMS and Sanofi
Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness
New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit
The FDA will hold a public hearing in November to gather input on how it should regulate certain off-label communications.
Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana
The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers
FDA Commissioner Robert Califf has two plans for what he wants to achieve during his tenure. One is long-term. The other ends in early 2017.
The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants
The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015
The FDA said Amgen's biosimilar of Humira is safe and effective; Juno trial halted due to patient deaths; the CMS bans Theranos founder
Donald Trump and Hillary Clinton offer clear contrasts on the issues of the Affordable Care Act, entitlement reform, and drug pricing.
GIlead Sciences' new HCV treatment receives approval; FDA adcomm votes in favor of Jardiance health-outcomes' claims; FDA names head of new oncology center
Opdivo nets sixth Breakthrough Therapy designation; AstraZeneca seeks rare indication to block Crestor generics; Endo mulls sale to reduce debt
A government watchdog criticizes the FDA; the FDA strengthens kidney warnings for Invokana and Farxiga; people with diabetes are living longer
FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec
Industry lobbying group plans counteroffensive; the FDA rejected a record high amount generic drug applications; adcomm recommends Pfizer painkiller
Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.
U.S. investors want lobbyists to make a better case on drug pricing; pancreatic vaccine failed in Phase-III trial; Epirus cuts 40% of its workforce
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Five things for pharma marketers to know: Wednesday, October 26, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy